13/07/2026
Wonderful Saffron.. an incredible herbal ally, and one I prescribe and recommend often 🙌🌿
A new 12-week randomised, double blind, placebo-controlled trial has provided the strongest clinical evidence to date supporting saffron as a treatment for low mood and depressive symptoms (subclinical depression). Enrolling 202 adults aged 18 to 70 years, it is the largest clinical trial ever conducted on saffron for mood disorders and probably the most methodologically rigorous saffron study published to date.
The study used a proprietary saffron extract at a dose of 28 mg/day. Subclinical, subthreshold, or minor depression is defined as the presence of depressive symptoms but without fulfilling all the diagnostic criteria for major depressive disorder (MDD). Although participants in the trial did not have formally diagnosed MDD, their baseline DASS-21 (Depression, Anxiety and Stress Scale-21) scores averaged around 22, placing many in the severe symptom range despite being classified as ‘subclinical.’ At the same time, the cohort was relatively medically uncomplicated, with exclusions for major psychiatric diagnoses, significant medical illness, heavy alcohol use, smoking, ongoing psychotherapy and several medication classes, thereby creating a low-mood population largely free of potential confounders.
The primary outcome showed a statistically significant antidepressant effect favouring saffron. DASS-21 scores fell by 11.34 points in the saffron group compared with 8.42 points in the placebo group, producing a modest but clinically meaningful between-group effect size (Cohen’s d = 0.39, P = 0.010). Particularly noteworthy was the responder analysis: 72.3% of saffron-treated participants achieved a clinically meaningful reduction of at least 7 points on the DASS-21 depression scale compared with 54.3% in the placebo group (P = 0.010). However, the study also highlighted the enormous placebo responses that can be seen in low-mood trials. Much of the improvement occurred in both groups during the first 4 weeks, suggesting strong expectancy and nonspecific trial-participation effects.
Importantly though, the placebo response largely plateaued thereafter, whereas the saffron group continued gradual improvement across the full 12 weeks. This temporal divergence arguably strengthens the credibility of the findings because it suggests saffron may exert a progressively accumulating physiological effect rather than simply producing a short-lived expectancy response. Even longer treatment durations may have resulted in a larger separation between saffron and placebo.
Saffron did not significantly outperform placebo on most secondary measures including anxiety, stress and general wellbeing, although favourable trends were observed. The sleep findings were particularly interesting. Overall sleep outcomes were not statistically significant across the entire cohort, but exploratory subgroup analyses revealed meaningful improvements in participants with more substantial baseline sleep disturbance. In these participants, effect sizes for sleep improvement approached or slightly exceeded those seen for depression itself (d = 0.44). This suggests saffron’s sleep effects may be conditional and phenotype-dependent rather than universally sedative. The study also strengthened its methodological credibility by applying several observances: adjusting analyses for treatment expectancy effects, using intention-to-treat and per-protocol analyses, and incorporating daily mood ratings across the study duration.
The safety profile was excellent, with over 95% of participants rating tolerability as good or excellent and only a handful of mild treatment-related adverse events reported, including headache, abdominal pain and itchy skin. Overall, this landmark study substantially strengthens the evidence base supporting saffron as a genuine antidepressant phytomedicine, while simultaneously illustrating the profound challenge of the placebo response in mood research. But to my thinking, the very magnitude of the placebo response may actually enhance the credibility of the trial itself, because it reflects the real world.
In summary, this is arguably the most methodologically credible saffron mood trial yet conducted because of its size, duration, expectancy adjustment and rigorous analyses. The findings support saffron as a modest but clinically meaningful intervention for depressive symptoms, particularly in relatively healthy individuals, while also suggesting that its effects may accumulate progressively over time and potentially extend to sleep benefits in symptom-specific subgroups.
For more information see: https://pubmed.ncbi.nlm.nih.gov/40414301/
